利妥昔单抗治疗局灶节段性肾小球硬化症机制的研究进展

Research progress of the mechanism of rituximab in the treatment of focal segmental glomerulosclerosis

利妥昔单抗(rituximab,RTX)作为一种作用于B细胞表位CD20的单抗,自2005年被应用于肾脏领域以来,已成为众多肾小球肾炎疾病临床治疗的研究热点。目前对于RTX的研究,除集中在其临床治疗安全性及有效性之外,部分学者仍致力于探讨其对肾脏病治疗的作用机制,试图寻找其在肾脏组织中存在的特异性靶点。该文就RTX在治疗局灶节段性肾小球硬化症中的作用机制研究进展进行综述。

Rituximab(RTX),as a monoclonal antibody of CD20 acting on B cell epitopes,has been applied to the field of kidney since 2005,and has become a research hotspot in the clinical treatment of glomerulonephritis.At present,in addition to its clinical safety and efficacy,some researchers are still committed to explore the mechanism of RTX in the treatment of renal diseases,trying to find out whether there is a specific target in renal tissue.In this paper,the mechanism of RTX in the treatment of focal segmental glomerulosclerosis is reviewed.